- LFM-A13
-
- $1.00 / 1g
-
2019-12-26
- CAS:62004-35-7
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 200kg
|
| | LFM-A13 Basic information |
| Product Name: | LFM-A13 | | Synonyms: | LFM-A13;2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-buteneamide;2-CYANO-N-(2,5-DIBROMOPHENYL)-3-HYDROXY-2-BUTENAMIDE;ALPHA-CYANO-BETA-HYDROXY-BETA-METHYL-N-(2,5-DIBROMOPHENYL)PROPENAMIDE;2-Cyano-3-hydroxy-but-2-enoic acid (2,5-dibromo-phenyl)-amide;2-Butenamide, 2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-;2-Cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide | | CAS: | 62004-35-7 | | MF: | C11H8Br2N2O2 | | MW: | 360 | | EINECS: | | | Product Categories: | Protein Kinase;Growth Factors and Cytokines;Intracellular Signaling | | Mol File: | 62004-35-7.mol |  |
| | LFM-A13 Chemical Properties |
| storage temp. | −20°C | | solubility | DMSO: 15 mg/mL | | form | powder | | color | white |
| Hazard Codes | Xn | | Risk Statements | 20/21/22 | | Safety Statements | 36/37 | | WGK Germany | 3 | | HS Code | 2926.90.4801 |
| | LFM-A13 Usage And Synthesis |
| Uses | LFM-A13 is a novel anti-leukemic agent targeting Bruton''s tyrosine kinase (BTK). LFM-A13 is a BTK inhibitor. | | Biological Activity | Potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Inhibits recombinant BTK with an IC 50 value of 2.5 μ M and has no activity on other protein kinases ( including JAK1, JAK3, HCK, EGFR kinase and insulin receptor kinase) at concentrations of up to 278 μ M. | | storage | Store at RT |
| | LFM-A13 Preparation Products And Raw materials |
|